Samsara BioCapital
Latest statistics and disclosures from Samsara BioCapital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SRRK, CRGX, MLYS, NGNE, NKTX, and represent 59.31% of Samsara BioCapital's stock portfolio.
- Added to shares of these 7 stocks: Lenz Therapeutics (+$27M), JSPR (+$15M), NKTX (+$9.7M), MLYS (+$7.2M), Adverum Biotechnologies, VTVT, PRME.
- Started 3 new stock positions in Adverum Biotechnologies, JSPR, Lenz Therapeutics.
- Reduced shares in these 7 stocks: Rayzebio (-$115M), Graphite Bio (-$22M), JANX (-$6.8M), PEPG, Rain Therapeutics, ACLX, Science 37 Holdings.
- Sold out of its positions in Graphite Bio, PEPG, Rain Therapeutics, Rayzebio, Science 37 Holdings.
- Samsara BioCapital was a net seller of stock by $-82M.
- Samsara BioCapital has $646M in assets under management (AUM), dropping by 0.56%.
- Central Index Key (CIK): 0001744967
Tip: Access up to 7 years of quarterly data
Positions held by Samsara BioCapital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Samsara BioCapital
Samsara BioCapital holds 39 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Scholar Rock Hldg Corp (SRRK) | 18.7 | $121M | 6.8M | 17.76 |
|
|
| Cargo Therapeutics (CRGX) | 14.2 | $92M | 4.1M | 22.32 |
|
|
| Mineralys Therapeutics (MLYS) | 10.1 | $66M | +12% | 5.1M | 12.91 |
|
| Neurogene (NGNE) | 10.0 | $65M | 1.3M | 50.90 |
|
|
| Nkarta (NKTX) | 6.3 | $41M | +31% | 3.8M | 10.81 |
|
| Arcellx Common Stock (ACLX) | 4.9 | $32M | 454k | 69.55 |
|
|
| Lenz Therapeutics | 4.2 | $27M | NEW | 1.2M | 22.33 |
|
| Lyra Therapeutics (LYRA) | 2.7 | $17M | 2.8M | 6.22 |
|
|
| Acelyrin (SLRN) | 2.6 | $17M | 2.5M | 6.75 |
|
|
| Avadel Pharmaceuticals Sponsored Adr (AVDL) | 2.5 | $16M | 968k | 16.89 |
|
|
| Jasper Therapeutics Com New (JSPR) | 2.4 | $15M | NEW | 525k | 29.36 |
|
| Zymeworks Del (ZYME) | 2.4 | $15M | 1.5M | 10.52 |
|
|
| Hillevax (HLVX) | 2.1 | $13M | 799k | 16.63 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 1.9 | $12M | 850k | 14.30 |
|
|
| Inozyme Pharma (INZY) | 1.9 | $12M | 1.6M | 7.66 |
|
|
| Syros Pharmaceuticals Com New (SYRS) | 1.5 | $9.6M | 1.8M | 5.35 |
|
|
| Sutro Biopharma (STRO) | 1.5 | $9.5M | 1.7M | 5.65 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 1.2 | $7.5M | 173k | 43.33 |
|
|
| Gossamer Bio (GOSS) | 1.1 | $7.2M | 6.1M | 1.18 |
|
|
| Janux Therapeutics (JANX) | 1.0 | $6.8M | -50% | 180k | 37.65 |
|
| Io Biotech (IOBT) | 1.0 | $6.3M | 3.6M | 1.73 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 0.9 | $5.6M | 348k | 16.09 |
|
|
| Tango Therapeutics (TNGX) | 0.8 | $5.0M | 630k | 7.94 |
|
|
| Vtv Therapeutics Cl A New (VTVT) | 0.8 | $4.9M | +405% | 207k | 23.53 |
|
| Immatics SHS (IMTX) | 0.6 | $4.2M | 396k | 10.51 |
|
|
| Adverum Biotechnologies Com New | 0.6 | $4.1M | NEW | 292k | 14.14 |
|
| Prime Medicine (PRME) | 0.6 | $3.8M | +14% | 540k | 7.00 |
|
| Day One Biopharmaceuticals I (DAWN) | 0.5 | $3.2M | 196k | 16.52 |
|
|
| Leap Therapeutics Com New (LPTX) | 0.3 | $1.8M | 669k | 2.66 |
|
|
| Igm Biosciences (IGMS) | 0.2 | $1.5M | 155k | 9.65 |
|
|
| Bolt Biotherapeutics (BOLT) | 0.2 | $1.5M | 1.0M | 1.40 |
|
|
| Terns Pharmaceuticals (TERN) | 0.2 | $1.3M | 202k | 6.56 |
|
|
| Aclaris Therapeutics (ACRS) | 0.1 | $863k | 696k | 1.24 |
|
|
| Viracta Therapeutics (VIRX) | 0.1 | $704k | 690k | 1.02 |
|
|
| Allakos (ALLK) | 0.0 | $217k | 172k | 1.26 |
|
|
| Kronos Bio (KRON) | 0.0 | $102k | 78k | 1.30 |
|
|
| Allovir (ALVR) | 0.0 | $62k | 82k | 0.75 |
|
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $40k | 133k | 0.30 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $3.0k | 100k | 0.03 |
|
Past Filings by Samsara BioCapital
SEC 13F filings are viewable for Samsara BioCapital going back to 2018
- Samsara BioCapital 2024 Q1 filed May 15, 2024
- Samsara BioCapital 2023 Q4 filed Feb. 14, 2024
- Samsara BioCapital 2023 Q3 filed Nov. 14, 2023
- Samsara BioCapital 2023 Q1 restated filed Aug. 14, 2023
- Samsara BioCapital 2023 Q2 filed Aug. 14, 2023
- Samsara BioCapital 2023 Q1 filed May 15, 2023
- Samsara BioCapital 2022 Q4 amended filed Feb. 15, 2023
- Samsara BioCapital 2022 Q4 filed Feb. 14, 2023
- Samsara BioCapital 2022 Q3 filed Nov. 14, 2022
- Samsara BioCapital 2022 Q2 filed Aug. 15, 2022
- Samsara BioCapital 2022 Q1 filed May 16, 2022
- Samsara BioCapital 2021 Q4 filed Feb. 14, 2022
- Samsara BioCapital 2021 Q3 filed Nov. 15, 2021
- Samsara BioCapital 2021 Q2 filed Aug. 17, 2021
- Samsara BioCapital 2021 Q1 filed May 18, 2021
- Samsara BioCapital 2020 Q4 filed Feb. 17, 2021